SFTS
Conditions
Interventions
Intervention group (part A-part C):Part a: on the basis of routine treatment, the patients in group a received methylprednisolone 2 mg/kg/D IVIG 20 g/D for a total of 5 days. If the disease progresses
Non intervention group (routine treatment group):Standard treatment regimen, 14 days in total
Sponsors
Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Aged >= 18 years old, gender is not limited; 2. Meet the following diagnostic criteria for fever with thrombocytopenia syndrome: Patients with positive SFTs virus (sftsv) in peripheral blood detected by RT-PCR or next generation sequencing (NGS); 3. The intervention group shall meet the following conditions: Part A: If the patient has 2 of the following conditions, the treatment can be started: (1) Continuous high fever for 7 days or more; (2) Platelets 2 times the upper limit of normal value (ULN); Part C: Plasma D-D dimer >= 4xUL; 4. Sign written informed consent and cooperate with follow-up.
Exclusion criteria
Exclusion criteria: 1. Patients with tumor diseases; 2. Patients with serious chronic diseases, such as chronic kidney disease (stage 3-5), chronic heart failure, decompensated cirrhosis, chronic diseases of the central nervous system, blood tumor diseases, uncontrolled solid tumors, etc.; 3. Patients who are pregnant or may be pregnant; 4. Patients with a history of hypersensitivity to the investigational drug and its components; 5. The investigator judges that the patients with diseases affecting the short-term survival rate are not suitable for inclusion in this protocol; Among them, the additional exclusion criteria of Part B group:Platelets 2.0, or thromboelastogram results suggest obvious fibrinolysis. 6. Other clinically obvious forms of shock occur, including cardiogenic, obstructive (massive pulmonary embolism, cardiac tamponade, tension pneumothorax), hemorrhagic, neurogenic or anaphylactic shock.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Biological samples; | — |
Countries
China
Contacts
Public ContactNing Qin
Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
Outcome results
None listed